Carregant...
Application of Mycobacterium smegmatis as a surrogate to evaluate drug leads against Mycobacterium tuberculosis
Discovery of new anti-tuberculosis (TB) drugs is a time-consuming process due to the slow-growing nature of Mycobacterium tuberculosis (Mtb). A requirement of biosafety level 3 (BSL-3) facility for performing research associated with Mtb is another limitation for the development of TB drug discovery...
Guardat en:
| Publicat a: | J Antibiot (Tokyo) |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7554168/ https://ncbi.nlm.nih.gov/pubmed/32472054 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41429-020-0320-7 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|